Get In Touch
Xeraya Capital Sdn Bhd
26.03–26.08, G Tower
#199 Jalan Tun Razak, KL
xeraya@xeraya.com
+603 2381 8700
Submit a Proposal
proposal@xeraya.com
Back

News & Events

Latest news and events related to our activities and our portfolio partners.
  • Xeraya Admin
  • Posted by Xeraya Admin
July 21, 2021
3 min read

Congenica Receives CE Mark for Genomic Analysis Software

  • Xeraya Admin
  • Posted by Xeraya Admin
July 17, 2021
5 min read

Gene mapping will reduce fatal drug interactions in older people

  • Xeraya Admin
  • Posted by Xeraya Admin
July 15, 2021
3 min read

Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock

  • Xeraya Admin
  • Posted by Xeraya Admin
July 14, 2021
4 min read

Rapid Micro Biosystems Announces Pricing of Initial Public Offering

  • Xeraya Admin
  • Posted by Xeraya Admin
June 15, 2021
6 min read

OncoMyx Announces Exclusive Option to License Intellectual Property Rights for Myxoma Virus Technology from University of Florida

  • Xeraya Admin
  • Posted by Xeraya Admin
June 9, 2021
3 min read

Khazanah investee Xeraya Capital invests in US$50m Series C funding round in UK digital firm

  • Xeraya Admin
  • Posted by Xeraya Admin
April 13, 2021
3 min read

Congenica and Camtech Diagnostics agree strategic partnership to support genomic analysis platform expansion in Asia

  • Xeraya Admin
  • Posted by Xeraya Admin
April 6, 2021
5 min read

Shell invests in LanzaJet in bid to produce more green jet fuel

  • Xeraya Admin
  • Posted by Xeraya Admin
March 16, 2021
5 min read

Rapid Micro Biosystems Raises $81M to Continue Global Expansion of Automated Pharmaceutical QC Platform to Improve Data Integrity and Safety in Biologics, Vaccines, and Cell & Gene Therapy Manufacturing

  • Xeraya Admin
  • Posted by Xeraya Admin
March 11, 2021
4 min read

Liquidia’s LIQ861 Meets Primary Endpoint in Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension

  • Xeraya Admin
  • Posted by Xeraya Admin
March 3, 2021
3 min read

Congenica secures Series C Follow On investment from QVentures

  • Xeraya Admin
  • Posted by Xeraya Admin
February 5, 2021
2 min read

Xeraya Capital Statement On Cloned Website

  • Xeraya Admin
  • Posted by Xeraya Admin
January 13, 2021
4 min read

InterVenn Receives Foundational Patent, CLIA Lab Certification to Develop Clinical Glycoproteomics Solutions

  • Xeraya Admin
  • Posted by Xeraya Admin
December 18, 2020
4 min read

Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China

  • Xeraya Admin
  • Posted by Xeraya Admin
December 7, 2020
6 min read

Acutus Medical Launches AcQBlate Force Sensing Ablation System in Europe

  • Xeraya Admin
  • Posted by Xeraya Admin
December 3, 2020
3 min read

P2 Science Launches New Patented Line of Cosmetics Ingredients

  • Xeraya Admin
  • Posted by Xeraya Admin
December 2, 2020
9 min read

Exelixis In-Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application

  • Xeraya Admin
  • Posted by Xeraya Admin
November 30, 2020
3 min read

FDA Requests More Data to Support LIQ861's Potential Approval for PAH

  • Xeraya Admin
  • Posted by Xeraya Admin
November 17, 2020
5 min read

Imago Biosciences Raises $80 Million In Series C Financing

  • Xeraya Admin
  • Posted by Xeraya Admin
November 16, 2020
3 min read

InterVenn Biosciences Raises $34M For Ovarian Cancer, Immuno-oncology Therapies

  • Xeraya Admin
  • Posted by Xeraya Admin
November 5, 2020
4 min read

Interim Data from Imago BioSciences' Phase 2b Study of Bomedemstat (IMG-7289) for Treatment of Myelofibrosis to be Presented at 62nd American Society of Hematology Annual Meeting

  • Xeraya Admin
  • Posted by Xeraya Admin
October 19, 2020
3 min read

OncoMyx Announces Presentation of Preclinical Data for Novel Oncolytic Virotherapy at AACR Tumor Immunology and Immunotherapy Virtual Conference

  • Xeraya Admin
  • Posted by Xeraya Admin
October 2, 2020
3 min read

Imago BioSciences Doses First Patient in Phase 2b Study of Bomedemstat (IMG-7289) in Essential Thrombocythemia

  • Xeraya Admin
  • Posted by Xeraya Admin
October 2, 2020
1 min read

BFM Morning Run - The Breakfast Grille: Interview with Fares Zahir, CEO of Xeraya Capital